United Kingdom
Industry
BMI Core View: Sales forces will contract in developed states and expand in emerging markets. The primary cause of this trend is the declining influence of US and Western European doctors...
2010-08-13Industry
Multinational drugmaker Shire is to acquire Belgian drugmaker Movetis for EUR428mn (US$565mn), or EUR19 a share - a 60% premium on their earlier price of EUR11.90 - funded by the company's...
2010-08-05Industry
BMI believes AstraZeneca's Q210 results reinforce our view that emerging markets will drive industry growth. The company delivered a strong performance in H110, posting a 7% increase...
2010-07-29Industry
GlaxoSmithKline (GSK)'s Q210 results reinforce BMI's view that emerging markets will drive industry growth. The company delivered a strong performance in H110, posting a 7.0% increase...
2010-07-22Industry
US-based drugmaker Allergan's Botox (botulinum toxin type A) has been licensed by the MHRA in the UK for the prophylaxis of headaches in adults who have chronic migraines (headaches...
2010-07-13Industry
BMI View: Emerging markets will drive industry growth. The importance of emerging markets to large multinational drugmakers cannot be overstated - BMI's Pharmaceutical Expenditure Model...
2010-06-30Industry
We have revised downwards our forecast for pharmaceutical expenditure in the UK, following BMI's Country Risk team's amendment of medium-term economic growth forecasts on the back of...
2010-06-29Industry
GW Pharmaceuticals has received regulatory approval in the UK for its prescription cannabis medicine, Sativex (delta-9-tetrahydrocannabinol + cannabinol) oromucosal spray, for the treatment...
2010-06-21
